DexCom (DXCM)
(Delayed Data from NSDQ)
$69.00 USD
-0.70 (-1.00%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $68.91 -0.09 (-0.13%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$69.00 USD
-0.70 (-1.00%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $68.91 -0.09 (-0.13%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth A Momentum B VGM
Zacks News
Chemed Gains Ground on Solid VITAS & Roto-Rooter Businesses
by Zacks Equity Research
Chemed (CHE) witnesses solid revenue growth across key subsidiaries.
Here's Why Investors Should Buy DexCom (DXCM) Stock Now
by Zacks Equity Research
Solid growth at the Sensor, Transmitter and Receiver segments provide DexCom (DXCM) a competitive edge in the MedTech space.
DexCom's (DXCM) Q4 Earnings Beat, International Revenues Up
by Zacks Equity Research
DexCom's (DXCM) fourth-quarter 2018 results benefit from strong contributions from the Sensor, Transmitter and Receiver segments.
Here's Why You Should Invest in Illumina (ILMN) Stock Now
by Zacks Equity Research
Illumina (ILMN) continues to gain on solid international business.
DexCom (DXCM) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
DexCom (DXCM) delivered earnings and revenue surprises of 237.50% and 2.18%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Masimo and Saudi Arabia MOH Collaborate for CCHD Screening
by Zacks Equity Research
Studies have shown that Masimo's (MASI) SET pulse oximetry can improve CCHD screening, helping to save newborns.
Luminex Hurt By Segmental Sluggishness, Stiff Competition
by Zacks Equity Research
Luminex's (LMNX) dependence on its partners for revenue generation is a major problem.
DexCom (DXCM) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
DexCom (DXCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Investors Should Buy CONMED (CNMD) Stock Now
by Zacks Equity Research
CONMED's (CNMD) guidance for 2019 buoys optimism in the stock.
DexCom (DXCM) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom (DXCM) expects to gain from strong demand for the G6 sensors. These sensors are likely to rake in huge profits during the fourth quarter of 2018.
Ecolab (ECL) Reports Preliminary Q4 Results, Issues Guidance
by Zacks Equity Research
Ecolab (ECL) plans to spin off Upstream Energy sub-unit as a stand-alone publicly-traded company by mid-2020.
Can TruBridge Fuel Computer Programs' (CPSI) Q4 Earnings?
by Zacks Equity Research
Computer Programs (CPSI) is likely to gain from TruBridge platform in fourth-quarter 2018.
BD Gains From Solid Global Base, Headwinds Anticipated
by Zacks Equity Research
Becton, Dickinson's (BDX) solid geographical expansion encourages; raw material pricing pressure raises concern.
HealthEquity's (HQY) Preliminary Q4 Results Cheer Investors
by Zacks Equity Research
HealthEquity's (HQY) solid guidance for fiscal 2019 favors stock.
3 Medical Instruments Stocks Likely to Beat Estimates in Q4
by Zacks Equity Research
Medical Instruments companies are likely to gain from strong performance in emerging economies and modernization of 510 (k)-clearance pathway by the FDA in Q4.
Will Diagnostics Business Ail LabCorp (LH) in Q4 Earnings?
by Zacks Equity Research
LabCorp (LH) is likely to gain traction from the company's collaboration with Walgreens.
Can Boston Scientific (BSX) Q4 Earnings Fuel Overall Growth?
by Zacks Equity Research
We are hopeful that Boston Scientific (BSX) will report a strong IC business globally in Q4, backed by an innovative portfolio and robust commercial teams.
Can Molecular Diagnostics Drive Myriad's (MYGN) Q2 Earnings?
by Zacks Equity Research
Myriad (MYGN) likely to deliver solid Q2 results on the diversified Molecular Diagnostics portfolio with products like GeneSight, EndoPredict, BRACAnalysis CDx and Prolaris tests.
Cerner (CERN) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Cerner's (CERN) fourth-quarter 2018 results are likely to be hurt by year-over-year decline in bookings; Q4 guidance promising.
Can Zimmer Biomet (ZBH) Grow on Hip Business in Q4 Earnings?
by Zacks Equity Research
Within Hip business, we expect Zimmer Biomet (ZBH) to experience a strong uptick in the Asia-Pacific region.
Can CAG Growth Steadily Drive IDEXX (IDXX) in Q4 Earnings?
by Zacks Equity Research
IDEXX (IDXX) is expected to keep its momentum alive in Q4, banking on a strong global rise in Companion Animal Group Diagnostics' revenues.
Can BD Medical Drive Becton, Dickinson's (BDX) Q1 Earnings?
by Zacks Equity Research
Becton, Dickinson's (BDX) solid fiscal first-quarter preliminary results boost optimism in the stock.
Will Core Business Units Boost McKesson's (MCK) Q3 Earnings?
by Zacks Equity Research
McKesson (MCK) expects to gain from solid segmental performances in third-quarter fiscal 2019.
ResMed (RMD) Q2 Earnings in Line, Revenues Miss Estimates
by Zacks Equity Research
ResMed (RMD) benefits from growth at CER across all geographies. However, device sales in France and Japan get affected.
AmerisourceBergen (ABC) Q1 Earnings: What's in the Cards?
by Zacks Equity Research
AmerisourceBergen's (ABC) first-quarter fiscal 2019 results are likely to gain from its core Pharmaceutical Distribution business unit.